LSTA LSTA
Company Profile ↓Company Overview
LSTA (LSTA) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Recent Developments
- Dec 2025 Revenue of $170.00K (-83.0% YoY); net profit $-16.59M.
- Trailing 12 Months Year-on-year growth — revenue -83.0%.
- 5-Year Trend Long-term compounding — revenue CAGR -45.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -45.22% |
| 1 Year: | -83.00% |
Stock Price Performance
| 1 Year: | -56.42% |
| 6 Months: | -75.55% |
| 3 Months: | -65.75% |
| 1 Month: | -65.75% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- Death Cross9d ago
- RSI (14)19.99 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -45.2% CAGR over 5 years.
- Trading 77.8% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
- RSI at 20 suggests oversold conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Dec 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 70.00K | 0 | 0 |
| Operating Income | - | -13.50M | -12.43M | -16.26M | - | -18.09M | -25.67M | -10.38M | - | -11.07M | -7.41M | -5.73M | -6.43M | -7.71M | -6.13M | -5.16M | -4.27M | -3.76M | -4.59M | -5.35M | -5.07M | -4.06M | -4.29M | -5.35M | -8.09M | -7.15M | -6.97M | -6.62M | -6.72M | -37.72M | -6.84M | -6.88M | -5.96M | -6.60M | -5.52M | -5.34M | -5.85M | -4.87M | -4.41M | -4.94M |
| Net Income | -12.54K | -13.68K | -12.61K | -16.97K | -11.61K | -19.19K | -17.13K | -11.38K | -33.20K | - | - | - | - | - | - | - | - | - | -4.37M | -5.14M | -4.90M | -3.99M | 6.60M | -5.33M | -8.06M | -5.68M | -6.93M | -4.23M | -6.63M | -37.38M | -6.19M | -4.03M | -5.26M | -5.40M | -5.04M | -4.93M | -4.72M | -4.66M | -4.25M | -4.49M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.38 | 0.50 | -0.29 | -0.19 | -0.10 | -1.74 | -1.05 | -1.64 | -7.88 | -0.77 | -0.50 | -0.65 | -0.65 | -0.61 | -0.59 | -0.55 | -0.54 | -0.49 | -0.50 |
| R&D Expense | - | 4.76M | 5.80M | 8.47M | - | 6.80M | 7.60M | 6.32M | - | 5.88M | 4.49M | 2.96M | 3.73M | 4.28M | 3.19M | 2.26M | 2.12M | 1.70M | 2.04M | 2.99M | 3.00M | 1.50M | 1.82M | 3.03M | 5.08M | 4.33M | 4.12M | 3.28M | 3.24M | - | - | - | - | - | - | - | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 69.82M | 10.05M | 14.33M | 14.67M | 17.94M | 22.49M | 35.28M | - | - | - | - | - | 0 | 0 | 1.00M | 170.00K |
| Gross Profit | 20.15M | 1.40M | 2.38M | 1.72M | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -18.88M | -34.00M | -30.39M | -36.81M | -57.74M | -113.85M | -29.50M | -27.59M | -16.99M | -20.09M | -19.14M | -29.05M | -57.60M | -25.71M | -22.41M | -18.21M |
| Net Income | -23.31M | -47.13M | -53.77M | -38.98M | -54.87M | -80.89M | -32.66M | 22.98M | -16.17M | -19.36M | -8.15M | -27.47M | -54.23M | -20.84M | -19.98M | -16.59M |
| Diluted EPS | - | - | - | - | - | - | -4.99 | 2.56 | - | - | -0.53 | -7.45 | -10.47 | -2.58 | -2.40 | -1.91 |
| R&D Expense | 7.68M | 7.72M | 10.45M | 16.92M | 29.19M | 23.90M | 16.70M | 15.84M | 7.59M | 10.80M | 9.25M | 17.68M | - | - | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Nov 2012 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 143.02M | 155.33M | - | 54.41M | 89.82M | 126.28M | 57.21M | 53.51M | 63.38M | 44.58M | 27.15M | 36.00M | 97.01M | 73.03M | 54.69M | 35.00M | 17.74M |
| Total Equity | 57.83M | 48.66M | 62.03M | - | 33.18M | 62.54M | 58.51M | 23.71M | 4.88M | 50.51M | 37.73M | 20.82M | 32.50M | 92.25M | 66.58M | 48.15M | 29.57M | 14.86M |
| Cash & Equivalents | 7.16M | 15.61M | 3.94M | 12.30M | 13.74M | 46.13M | 19.17M | 20.32M | 7.08M | 29.16M | 10.30M | 14.03M | 16.51M | 24.65M | 32.15M | 22.59M | 16.21M | 15.96M |
| Long Term Debt | - | - | - | - | 0 | 0 | 13.89M | 10.83M | 2.52M | 0 | - | - | - | - | - | - | - | - |
| Total Liabilities | - | - | - | - | - | - | - | - | 30.05M | 13.19M | 7.13M | 6.60M | 3.76M | 5.01M | 6.71M | 6.80M | 5.68M | 3.14M |
| Current Liabilities | - | 32.84M | 36.45M | - | 9.95M | 9.81M | 16.24M | 21.02M | 21.18M | 9.31M | 5.62M | 5.98M | 3.51M | 4.52M | 6.38M | 6.59M | 5.61M | 3.07M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -8.48M | -20.93M | -13.85M | -27.10M | -46.90M | -39.26M | -23.67M | -20.88M | -19.99M | -18.88M | -8.82M | -22.25M | -21.17M | -20.03M | -19.36M | -15.95M |
| Investing Cash Flow | -17.11M | -2.05M | 6.09M | -2.69M | -10.74M | 3.80M | -2.85M | 41.27M | -4.71M | 21.43M | -7.28M | -54.90M | 28.91M | 10.10M | 13.23M | 15.09M |
| Financing Cash Flow | 33.86M | 20.07M | 8.74M | 62.19M | 30.67M | 36.60M | 20.90M | -932.00K | 824.00K | 1.18M | 18.58M | 85.28M | -224.00K | 385.00K | -206.00K | 599.00K |
| Capital Expenditure | -16.38M | -574.86K | -531.32K | -2.69M | -3.66M | -3.19M | -1.10M | -135.00K | -134.00K | -0 | -20.00K | -60.00K | -285.00K | -0 | -0 | -28.00K |
| Free Cash Flow | -24.85M | -21.50M | -14.38M | -29.79M | -50.55M | -42.44M | -24.77M | -21.01M | -20.12M | -18.88M | -8.84M | -22.30M | -21.45M | -20.03M | -19.36M | -15.98M |
| Dividends Paid | 222.92K | 0 | 327.75K | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 28.9% | 14.0% | 16.6% | 11.7% | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | -27.0% | -338.4% | -212.0% | -250.9% | -321.9% | -506.3% | -83.6% | - | - | - | - | - | - | - | -2,240.9% | -10,711.2% |
| Net Margin % | -33.4% | -469.0% | -375.2% | -265.7% | -305.9% | -359.7% | -92.6% | - | - | - | - | - | - | - | -1,998.5% | -9,756.5% |
| ROE % | -47.9% | -76.0% | -162.1% | -62.3% | -93.8% | -341.1% | -668.7% | 45.5% | -42.9% | -93.0% | -25.1% | -29.8% | -81.4% | -43.3% | -67.6% | -111.7% |
| ROCE % | -17.1% | -28.6% | -68.3% | -46.0% | -52.5% | -314.6% | -91.2% | -51.0% | -43.6% | -94.9% | -58.9% | -31.4% | -86.4% | -53.4% | -76.2% | -124.1% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for LSTA
Lisata Therapeutics Provides Update Following Termination of Merger Agreement - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxPX0FmUGFscm1zbUVMd3paYTd5ZktKOXhtbTJBQk85a1dkVTA0X0t6b1lrT2VycEhhY2kxbWs1R2Y4aWNONE8wQ0RtZkFFVURqSmtNZVFHOGZ3WVVpdFFMZGt3OE5UMmt1LURET3hpdU5ZbjJTelFCQWxhZGNFNUpRelVsckcwSFNBZUdWZn…
Lisata Therapeutics Inc. (NASDAQ: LSTA) Share Price, LSTA Stock News, LSTA Share Price & Updates - Kalkine
<a href="https://news.google.com/rss/articles/CBMiVkFVX3lxTE5YU2Y1ME01TkR2V3FpY2dKSGVXeS1EWkFuTTlncERrRjEyVGhLSk1PUFNCZV9SaktpRWtkdENaTVdnNTgteENGMV9kbU93NS00cjZtMnFB?oc=5" target="_blank">Lisata Therapeutics Inc. (NASDAQ: LSTA) Share Price…
Lisata Therapeutics, Inc. Revenue Breakdown – NASDAQ:LSTA - TradingView
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE90eEZiSzBnTUdLXzkwcUkzaUVqTi1IZWNtYzNHV2JQSmVlVEtadzJUZ3FldzZrQmFyNVBJd3J4anJtOXJmVWVIUjcwZjRya0ROa1FzQl9YWV84bGltUW5NWVNQVDBGaUt0ZjM4bDNnMW43WmZkYmVv?oc=5" target="_blank">Lisata …
Lisata Therapeutics Stock Falls After Hours: Here's Why - Benzinga
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxORjl3Q1d1elNpOGNPdFV2Q3RUbVUwT2k0SlVheUx5R3ZocURtTTkzMDEzYzZTRF9RdW9RRTMyUGJyNi1MS2hlbEdMdnRsTGF6RDMtS0pfbWdEbVY0NnAzeUsybjRQYng4czE5MU9kdUE5VnU2UXhBWmFIeFRIbzQ3eWxiUkpuRHdxOWduQk…
Lisata Therapeutics (LSTA) Terminates Merger Agreement with Kuva Labs Amid Financing Issues - GuruFocus
<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxQcHFoUGZhQ2I2WFhEOXFQVkxldGkwdTFJb3lWbjN2bzFObGZrVjA1cHpjNnA1elozRzl0aVhFdHNLN3BoY293aWRBcURoMmJTWC1NLTg1VnZraWUtNGVPRTNULXdnd1prRDdTOFVUWEo3SFhyMTNvckh3RVhna3V1Ti1EbkJlZkxidXk0ME…
Market Movers | Winners: CPHI, UTZ, VIVK | Losers: BURU, LSTA, QMLS - Trefis
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxOcTg0SkIyVjRUTFNsbS01ZVJjOGh5N05fb3NteWNXcVVWeUp6UkJmZ0FJRERubHRGY2Y1elZBMjk4RTExS0JYQW1FUmFaQ2RraWpGM1dqLXk1cG1YVG5ldGNMWjFmbk1WUWp0RVV6MndvWlpSQ0dtdFZYbWtHcWdwajBwd3U3RmJsUFFUNW…
LSTA — Frequently Asked Questions
What is the current share price of LSTA?
As of 2026-08-05 17:25 PDT, LSTA trades at $1.12 on NASDAQ/NYSE. Its 52-week range is $0.99 to $5.04.
What is the P/E ratio of LSTA?
LSTA trades at a trailing price-to-earnings (P/E) ratio of -0.59.
What is the return on equity (ROE) of LSTA?
LSTA has a return on equity (ROE) of -111.65%. Its return on capital employed (ROCE) is -124.10%.
Is LSTA a good stock to buy?
This page provides a data-driven analysis of LSTA, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.